Circulating soluble-CD30 (sCD30) in patients with HCV-related chronic hepatitis and in patients with alcoholic liver disease

Hepatogastroenterology. 2002 Jan-Feb;49(43):231-4.

Abstract

Background/aims: Serum sCD30 (soluble CD30) is a marker of cells producing Th2-type (T-helper-2-type) cytokines. High levels of sCD30 have been found in the active phase of HBV infection. The Th2-type cytokine profile has been documented in alcoholic liver diseases, which have particularly high IgE and IgA serum levels. The aims were: 1) to evaluate sCD30 levels in patients with (a) alcoholic liver diseases and (b) HCV-related chronic hepatitis before and after interferon treatment; 2) to correlate sCD30 concentrations with IgE and IgA serum levels.

Methodology: Serum samples from 34 HCV-related chronic hepatitis patients, before and after interferon treatment, and 17 alcoholic liver disease patients were tested for sCD30 using the ELISA method (Dako, CD30-Ki-1 Antigen, Denmark).

Results: Significantly higher levels of sCD30 were found in alcoholic liver disease than in HCV-related chronic hepatitis patients (73.3 +/- 120 vs. 27.5 +/- 44 U/mL, P < 0.05). Alcoholic liver disease patients also exhibited significantly higher levels of IgA than HCV-related chronic hepatitis patients (P < 0.0001). No correlation was found between sCD30 and serum IgA or IgE or response to interferon.

Conclusions: Th2 cells are strongly expanded in alcoholic liver diseases, though the particular immunoglobulin profile observed in this condition has yet to be explained. Th2 function also plays a crucial part in chronic HCV infection, but seems unrelated to interferon response.

MeSH terms

  • Adult
  • Antiviral Agents / therapeutic use*
  • Biomarkers / blood
  • Female
  • Hepatitis C, Chronic / drug therapy
  • Hepatitis C, Chronic / immunology*
  • Humans
  • Immunoglobulin A / blood
  • Immunoglobulin E / blood
  • Immunologic Factors / therapeutic use*
  • Interferon alpha-2
  • Interferon-alpha / therapeutic use*
  • Ki-1 Antigen / blood*
  • Liver Diseases, Alcoholic / drug therapy
  • Liver Diseases, Alcoholic / immunology*
  • Male
  • Middle Aged
  • Recombinant Proteins
  • Treatment Outcome

Substances

  • Antiviral Agents
  • Biomarkers
  • Immunoglobulin A
  • Immunologic Factors
  • Interferon alpha-2
  • Interferon-alpha
  • Ki-1 Antigen
  • Recombinant Proteins
  • Immunoglobulin E